(Q35069271)

6 August 2017

4 references

23 March 2019

22 June 2019

25 June 2019

26 October 2020

Tuberculosis chemotherapy: current drug delivery approaches (English)

1 reference

6 August 2017

2 references

26 October 2020

1 reference

1 reference

1 reference

26 October 2020

Viness Pillay

2

0 references

author name string

Lisa Claire du Toit

series ordinal

1

1 reference

6 August 2017

Michael Paul Danckwerts

series ordinal

3

1 reference

6 August 2017

publication date

19 September 2006

6 references

6 August 2017

23 March 2019

22 June 2019

25 June 2019

1 June 2020

26 October 2020

5 references

6 August 2017

23 March 2019

22 June 2019

25 June 2019

26 October 2020

7

1 reference

6 August 2017

page(s)

118

1 reference

Creative Commons Attribution 2.0 Generic

6 August 2017

copyright license

4 references

23 March 2019

22 June 2019

25 June 2019

Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages

26 October 2020

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Programmes and principles in treatment of multidrug-resistant tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Tuberculosis of the central nervous system

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Activity of amoxicillin/clavulanate in patients with tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Antituberculosis activities of clofazimine and its new analogs B4154 and B4157

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Antituberculosis activity of clarithromycin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Treatment of multidrug-resistant tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Multidrug-resistant tuberculosis and its control

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Pharmacology of the antimycobacterial drugs.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Maintenance of therapeutically active levels of isoniazid for prolonged periods in rabbits after a single implant of biodegradable polymer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Chemotherapeutic Activity of Clofazimine and Its Analogues against Mycobacterium tuberculosis: In Vitro, Intracellular, and In Vivo Studies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

The early bactericidal activity of drugs in patients with pulmonary tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

History of the development of rifampin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

The prognosis of a positive tuberculin reaction in childhood and adolescence

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Evaluation of subdermal biodegradable implants incorporating rifampicin as a method of drug delivery in experimental tuberculosis of guinea pigs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Thiacetazone: in vitro activity against mycobacterium avium and m. tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

8 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Studies on rifampicin release from ethylcellulose coated nonpareil beads

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Airways delivery of rifampicin microparticles for the treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Evaluation of the recently reported USP gradient HPLC method for analysis of anti-tuberculosis drugs for its ability to resolve degradation products of rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Overestimation of rifampicin during colorimetric analysis of anti-tuberculosis products containing isoniazid due to formation of isonicotinyl hydrazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Behavior of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

In vitro release modulation from crosslinked pellets for site-specific drug delivery to the gastrointestinal tract. I. Comparison of pH-responsive drug release and associated kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

A multiparticulate drug-delivery system based on pellets incorporated into congealable polyethylene glycol carrier materials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

History of the Development of Rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-118

Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Pro-drugs of isoniazid: synthesis and diffusion characteristics of acyl derivatives.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Solid-state characterization of rifampicin samples and its biopharmaceutic relevance

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1592088

Drug-resistant tuberculosis

27 September 2018

1 reference

12 December 2020

Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects

1 reference

12 December 2020

Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice

1 reference

12 December 2020

Physico-chemical properties of a rifampicin-releasing polydimethylsiloxane shunt

1 reference

12 December 2020

Studies on a reverse micelle-lamellar phase transition based depot preparation of rifampicin

1 reference

12 December 2020

Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization

1 reference

12 December 2020

1 reference

12 December 2020

Rifampicin-carrying poly(D,L-lactide) microspheres: loading and release

1 reference

12 December 2020

Multicenter quality control study of amikacin assay for monitoring once-daily dosing regimens. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

12 December 2020

Activity of amikacin against Mycobacteria in vitro and in murine tuberculosis

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses

1 reference

12 December 2020

Identifiers

DOI

10.1186/1465-9921-7-118

1 reference

Dimensions Publication ID

6 August 2017

1034153477

0 references

Fatcat ID

release_hzptwsr5ibgijgmncijaym5rdm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hzptwsr5ibgijgmncijaym5rdm

24 November 2022

mapped directly with Wikidata item

PMC publication ID

1592088

1 reference

6 August 2017

1 reference